Clinical Trial Update: Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pemigatinib in combination with a PD-1 inhibitor for unresectable or metastatic intrahepatic cholangiocarcinoma is being investigated, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Pemigatinib (pemigatinib)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Carcinoma, Intrahepatic Cholangiocarcinoma | Phase 2 | Status: UNKNOWN